Future Fields Analysis: $11M Raised
What is Future Fields?
Future Fields is a biotechnology company that produces sustainable recombinant proteins using fruit flies, aiming to revolutionize biomanufacturing with reduced environmental impact.
Employees
34
Founded
2018
Revenue
$1.8M - $7.6M
Product Features & Capabilities
- EntoEngine™ platform, custom recombinant proteins, scalable protein production, genetic engineering for optimal yield, growth factors for cultivated meat media, human recombinant proteins for medical research, sustainable and ethical biomolecular tools.
Pricing
- Recombinant Human FGF2: From $92.00 USD
- Recombinant Bovine FGF2: From $110.00 USD
- Recombinant Human Prolactin, Fc Tag: From $105.26 USD
- Recombinant Human Prolactin: From $126.32 USD
- Recombinant Human Interleukin-2: From $125.48 USD
- Recombinant Human Interleukin-10: From $303.85 USD
- Rec
How much Future Fields raised
1 - $11.2M USD
February 22, 2023Lead Investor: Not specified in the source.
Who are the founders of Future Fields
MA
Matt Anderson-Baron
Co-Founder
JA
Jalene Anderson-Baron
Co-Founder
Market Focus
Future Fields primarily focuses on the biotechnology industry, specifically in advanced biomanufacturing and custom protein production using their EntoEngine™ platform, which utilizes fruit flies.
Investors
- Builders VC
- Climate Capital
- Green Circle Foodtech Ventures
- Toyota Ventures
- Haskayne
Competitors Overview
Future Fields operates in the biomanufacturing and protein production market, primarily utilizing fruit flies through their EntoEngine™ platform. The main competitors identified are:
- Core Biogenesis:
- Overview: Based in Strasbourg, France, Core Biogenesis specializes in next-generati
See something that needs updating? Suggest edits to this profile.